11 February 2022 - The agenda for the May 2022 PBAC intracycle meeting is now available.

For the time being, the PBAC is scheduled to consider just three items in May:

• Farcimab (Vabysmo) - new medicine for patients with diabetic macular oedema
• Farcimab (Vabysmo) - new medicine for patients with age-related macular degeneration
• Nicotine replacement therapies - review findings of a post-market review 

Insights

• Farcimab (Vabysmo) was only approved by the FDA in late January; it has not been approved by the EMA or the TGA
• The post-market review of the nicotine replacement therapies was scheduled to be considered by the PBAC at its regular meeting in March

Read agenda for May 2022 PBAC meeting